Homozygous Familial Hypercholesterolaemia (HoFH)
Familial hypercholesterolaemia (often shortened to FH) is an inherited condition which leads to very high cholesterol levels. Untreated FH can cause early heart disease.
FH is passed down through families, from one generation to another. Most people with FH have inherited just one altered gene, which they inherit from one of their two parents. They will also have inherited one healthy gene from the other parent.
In rare cases it is possible to inherit two altered genes, one from each of your parents. This happens only when two people who have FH meet and have a baby together.
Having two altered genes for FH results in a much more severe form of FH.
- If the two altered genes they inherit (one from mum and one from dad) are identical – this is referred to as Homozygous FH or HoFH
- If the two altered genes are different - this is called Compound Heterozygous FH but may also be referred to as HoFH.
People with HoFH have blood cholesterol levels that are exceptionally high, usually between 10 and 20 mmol/L and possibly even higher.
What are chances of inheriting HoFH?
In the UK about one baby in every 250,000 is born with this severe form of FH, so this means that 240-300 children and adults in the UK are affected.
Because both parents have FH, their chances of passing an altered FH gene onto their child is high.
So for example if two people with FH have a family of 4 children, on average:
- 2 children will inherit the normal form of FH (HeFH) by inheriting one altered gene and one healthy gene
- 1 child will inherit the more severe form of FH (HoFH) by receiving an altered gene from both parents
- 1 child will not inherit FH at all because they receive a healthy gene from both parents
But this is an average situation. It is possible that all the children in the family could have FH or none of the children will have it.
Treatment of HoFH
Because HoFH is a more severe and aggressive form of FH, it is very important that children are diagnosed and treated as early as possible. Without early treatment, children and young adults are likely to develop very early heart disease.
When treating HoFH doctors aim to reduce blood cholesterol to a level where the build-up of cholesterol in their blood vessels is slowed down, stopped and hopefully reversed.
Although most people who have FH are treated with a statin, those with this more severe form of FH (HoFH) don’t always benefit from a statin and so will need other treatments. Those that do respond to statins usually still need some additional therapy in order to bring their cholesterol level down sufficiently.
Resins, fibrates and ezetimibe may be used and can offer some cholesterol reduction for people with HoFH, usually in combination with other treatments.
Alirocumab and Evolocumab
This a relatively new type of medicine which can be offered to people with HoFH. They work by improving the removal of cholesterol from the blood. They have to be given by injection, but only once every 2 to 4 weeks. They have the potential to lower cholesterol by around 30% in people with HoFH.
This is a treatment where the blood is “cleaned” to remove cholesterol. It is similar to having dialysis, a treatment for kidney disease. Your blood is passed through a special machine that filters the cholesterol out. The treatment has to be done regularly; usually as a day patient, in one of the specialist treatment centres. Most people have the treatment twice a month.
Almost everyone who has HoFH will require LDL apheresis. Although it is very effective, you may have to travel a long way to receive treatment because there are only a few specialist centres in England, one in Wales and none in Scotland or Northern Ireland.
Lomitapide is made in capsule form to be taken by mouth and is licensed for use in adults with HoFH. Provided the treatment plan is followed carefully, it has been shown to lower cholesterol by half and can help people with HoFH achieve their cholesterol targets. It is sold under the brand name Lojuxta® and although it is licensed for use in the UK, because of the high cost of the drug, it is not routinely available. It is hoped that funding will be made available in due course, however until then individual applications for funding from a health care professional are required.
People taking Lojuxta need to follow a very low fat diet, usually less than 40-50g of fat per day for women or 50-60g of fat per day for men. Most people consume around 70-90g of fat per day. The manufacturers of Lojuxta provide dietary support to help achieve this. Those taking Lojuxta also need to have their liver function checked regularly and avoid certain drugs that may interact.